NVST:NYSEEnvista Holdings Corporation Analysis
Data as of 2026-04-21 - not real-time
$27.88
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Envista is trading around $27.88, comfortably above its recent support of $24.17 but still below the calculated fair value of $33.77, giving a modest upside of roughly 2‑3%. The technical picture shows a bullish MACD histogram, an RSI of 61 (still below overbought levels), and a neutral trend, though volume is slipping and 30‑day volatility is high at about 41%, underscoring short‑term price uncertainty. The stock’s beta of 1.6 signals sensitivity to market moves, while the PE ratio near 100 dwarfs the industry average of 25.8, suggesting current pricing is stretched on earnings expectations. However, the forward PE of 17.9 and management’s guidance for 2‑4% revenue growth with adjusted EPS of $1.35‑$1.45 point to a potential earnings re‑rating that could bring valuation back in line.
Fundamentally, Envista posted $2.72 B in revenue with 15% growth, but margins remain thin (gross ~55%, operating ~11%) and ROE is low at 1.6%. The balance sheet shows a debt‑to‑equity of 51% and a cash position that comfortably covers debt, while free cash flow conversion hovers near 100%, supporting the company’s ability to fund growth. Analyst consensus is a “Buy” with a median price target of $29, and upcoming Q1 2026 results could clarify the earnings trajectory. No dividend is paid, so income‑focused investors will look to capital appreciation driven by operational momentum and the modest valuation gap.
Fundamentally, Envista posted $2.72 B in revenue with 15% growth, but margins remain thin (gross ~55%, operating ~11%) and ROE is low at 1.6%. The balance sheet shows a debt‑to‑equity of 51% and a cash position that comfortably covers debt, while free cash flow conversion hovers near 100%, supporting the company’s ability to fund growth. Analyst consensus is a “Buy” with a median price target of $29, and upcoming Q1 2026 results could clarify the earnings trajectory. No dividend is paid, so income‑focused investors will look to capital appreciation driven by operational momentum and the modest valuation gap.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Bullish MACD and RSI below overbought levels
- Proximity to support and decreasing volume
- Upcoming earnings release that may confirm guidance
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Positive 2026 guidance with EPS targets above current levels
- Free cash flow conversion near 100% and manageable debt
- DCF fair value indicating modest upside
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Steady demand for dental technology and strong brand portfolio
- Low ROE and high valuation multiples limiting upside
- Stable cash generation but exposure to regulatory and market cycles
Key Metrics & Analysis
Financial Health
Revenue Growth15.00%
Profit Margin1.73%
P/E Ratio99.6
ROE1.56%
ROA2.78%
Debt/Equity51.43
P/B Ratio1.5
Op. Cash Flow$275.7M
Free Cash Flow$232.8M
Industry P/E25.8
Technical Analysis
TrendNeutral
RSI61.1
Support$24.17
Resistance$28.53
MA 20$26.33
MA 50$27.16
MA 200$22.62
MACDBullish
VolumeDecreasing
Fear & Greed Index87.09
Valuation
Fair Value$33.77
Target Price$28.54
Upside/Downside2.38%
GradeUndervalued
TypeBlend
Risk Assessment
Beta1.62
Volatility40.99%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.